CLINICAL TRIALS PROFILE FOR CHIDAMIDE
✉ Email this page to a colleague
Clinical Trials for Chidamide
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT01836679 ↗ | Chidamide in Combination With Carboplatin and Paclitaxel in Advanced Non-small Cell Lung Cancer | Completed | Chipscreen Biosciences, Ltd. | Phase 2 | The purpose of this study is to evaluate the efficacy and safety of Chidamide combined with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. |
NCT02482753 ↗ | Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer | Active, not recruiting | Chipscreen Biosciences, Ltd. | Phase 3 | This study was to evaluate the efficacy and safety of Chidamide in combination with exemestane in postmenopausal patients with hormone-receptor positive advanced breast cancer. |
NCT02513901 ↗ | Chidamide in Combination With Antiretroviral Therapy for Eradication of the Latent HIV-1 Reservoir | Completed | Chipscreen Biosciences, Ltd. | Phase 1/Phase 2 | HIV replication can be effectively suppressed and acquired immunodeficiency syndrome(AIDS) can be prevented with highly active antiretroviral therapy (HAART). However, HIV-infected people must remain on treatment continuously to avoid viral rebound and progression to AIDS. HIV persistence is thought to stem primarily from the presence of integrated copies of the proviral genome within long-lived cells. Because active viral gene expression causes cell death due to viral cytopathic effects and the immune response, long-lived cells likely harbor transcriptionally silent, latent provirus. HIV-1 persistence in long-lived cellular reservoirs remains a major barrier to a cure. HDACi have the potential to activate ("Kick") these latently infected cells. This will make the HIV infected cells visible to the immune system; the immune response and antiretrovirals(ARVs) will be able to attack and eliminate ("Kill") the infected cells. The purpose of this study is to evaluate the safety and efficacy of multi-dose Chidamide in combination with antiretroviral therapy in HIV-infected adults with suppressed viral load. |
NCT02513901 ↗ | Chidamide in Combination With Antiretroviral Therapy for Eradication of the Latent HIV-1 Reservoir | Completed | Tang-Du Hospital | Phase 1/Phase 2 | HIV replication can be effectively suppressed and acquired immunodeficiency syndrome(AIDS) can be prevented with highly active antiretroviral therapy (HAART). However, HIV-infected people must remain on treatment continuously to avoid viral rebound and progression to AIDS. HIV persistence is thought to stem primarily from the presence of integrated copies of the proviral genome within long-lived cells. Because active viral gene expression causes cell death due to viral cytopathic effects and the immune response, long-lived cells likely harbor transcriptionally silent, latent provirus. HIV-1 persistence in long-lived cellular reservoirs remains a major barrier to a cure. HDACi have the potential to activate ("Kick") these latently infected cells. This will make the HIV infected cells visible to the immune system; the immune response and antiretrovirals(ARVs) will be able to attack and eliminate ("Kill") the infected cells. The purpose of this study is to evaluate the safety and efficacy of multi-dose Chidamide in combination with antiretroviral therapy in HIV-infected adults with suppressed viral load. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Chidamide
Condition Name
Clinical Trial Locations for Chidamide
Trials by Country
Clinical Trial Progress for Chidamide
Clinical Trial Phase
Clinical Trial Sponsors for Chidamide
Sponsor Name